Concepedia

Author

Toshko Lissitchkov

University Specialized Hospital for Active Treatment of Endocrinology

Also Known As

Santoro, Cristina, T Lissitchkov, T. LISSITCHKOV, T. Lissitchkov, Toshko J. Lissitchkov, Toshko Jelev Lissitchkov, Toshko Lissitchkov

89

Publications

2.2K

Citations

24

H-Index

30

Concepts

All Affiliations

University Specialized Hospital for Active Treatment of EndocrinologyUniversity Hospital St. MarinaNational Specialized Hospital for Active Treatment of Hematologic DiseasesUniversity Multipurpose Hospital for Active Treatment "Sveti Georgi"Octapharma (Switzerland)
TL

About

Toshko Lissitchkov is an author at University Specialized Hospital for Active Treatment of Endocrinology specializing in medicine, hematology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

761

2

Immunology

3

3

61

3

Health Sciences

2

2

352

4

Cell Biology

2

2

48

5

Allergy

1

1

13

Toshko Lissitchkov

×

45

Publications

2.1K

Citations

24

H-Index

YearCitations

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

John Pasi, Savita Rangarajan, Pencho Georgiev,

New England Journal of Medicine

2017

345

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

Barbara A. Konkle, Liselotte S. Ebbesen, Elisabeth Erhardtsen,

Journal of Thrombosis and Haemostasis

2007

325

Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

Marilyn J. Manco‐Johnson, Christine L. Kempton, Mark T. Reding,

Journal of Thrombosis and Haemostasis

2013

197

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase <scp>III</scp> trial

Wolfgang Knauf, Toshko Lissitchkov, Ali Aldaoud,

British Journal of Haematology

2012

107

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

John Pasi, Toshko Lissitchkov, Vasily Mamonov,

Journal of Thrombosis and Haemostasis

2021

93

Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy

Toshko Lissitchkov, G. Arnaudov, Dontcho Peytchev,

Journal of Cancer Research and Clinical Oncology

2005

79

<scp>PK</scp>‐guided personalized prophylaxis with Nuwiq<sup>®</sup> (human‐cl rh<scp>FVIII</scp>) in adults with severe haemophilia A

Toshko Lissitchkov, L. Rusen, Pencho Georgiev,

Haemophilia

2017

51

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level &lt;1%) or moderately severe (FIX level ≤2%) haemophilia B

Jerzy Windyga, Toshko Lissitchkov, Oleksandra Stasyshyn,

Haemophilia

2013

48

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma

Sheela Rao, David Watkins, David Cunningham,

Annals of Oncology

2004

45

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B

Maria Elisa Mancuso, Aaron Lubetsky, Brigitte Pan‐Petesch,

Journal of Thrombosis and Haemostasis

2020

44

Page 1